A surge of innovation in next-generation drugs for diabetes treatment is reshaping therapeutic strategies by targeting novel metabolic pathways. Beyond conventional insulin and oral hypoglycemics, recent developments include dual and triple agonists that simultaneously modulate multiple hormonal pathways, such as GLP-1/GIP receptor agonists. Sodium-glucose co-transporter inhibitors (SGLT1/SGLT2) continue to gain traction due to their cardiovascular and renal protective effects. Additionally, small-molecule insulin mimetics and gene-editing techniques are opening new avenues for disease-modifying treatments. Personalized medicine approaches and advancements in drug delivery systems, including smart insulin and implantable devices, are enhancing efficacy while minimizing side effects. These breakthroughs offer promising prospects for achieving sustained glycemic control and preventing diabetes-related complications.
Title : Diabetes reduction (pre-diabetes and type 2) with integrative medicine
F Buck Willis, IUHS School of Medicine, Saint Kitts and Nevis
Title : Adipose MTP deficiency protects against hepatic steatosis by upregulating PPAR activity
Sujith Rajan, NYU Long Island School of Medicine, United States
Title : Does winter melon (Benincasa hispida) improves nutritional values and ameliorating glycaemic parameters?
Wan Rosli Wan Ishak, Universiti Sains Malaysia, Malaysia
Title : Clinical applications of monitoring unmethylated insulin cfDNA associated with beta-cell death for diabetes and metabolic diseases
Clifford Morris, Kihealth, United States
Title : Diabetes and migration: Impact of internal displacement on the prevalence and management of diabetes in Les Cayes, South Haiti (2022-2024)
Berger Saintius, Field Epidemiology Training Program (FETP), Haiti
Title : Correlation between food insecurity and diabetes in the commune of Les Cayes (2021-2024)
Djeamsly Salomon, Field Epidemiology Training Program (FETP), Haiti